27645-61-0

Basic information

• Product Name: Benzonitrile, 4-(4-hydroxybenzoyl)-
• Synonyms: Benzonitrile,4-(4-hydroxybenzoyl);4-cyano-4'-hydroxybenzophenone;4-(4-hydroxy-benzoyl)-benzonitrile
• CAS NO: 27645-61-0
• Molecular Formula: C14H9NO2
• Molecular Weight: 223.231
• Mol File: 27645-61-0.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Benzonitrile, 4-(4-hydroxybenzoyl)-(CAS DataBase Reference)
• NIST Chemistry Reference: Benzonitrile, 4-(4-hydroxybenzoyl)-(27645-61-0)
• EPA Substance Registry System: Benzonitrile, 4-(4-hydroxybenzoyl)-(27645-61-0)

Safety Data

• Hazardous Substances Data: 27645-61-0(Hazardous Substances Data)

Upstream product

• 52898-49-4 4,N-dimethoxy-N-methylbenzamide 
• 100-09-4 4-methoxybenzoic acid 
• 106-41-2 4-bromo-phenol 
• 27645-60-9 4-(4-methoxybenzoyl)benzonitrile 

Downstream Products

• 345341-53-9 [4-(4-Cyanobenzoyl)phenyl]2,3,4,6-tetra-O-acetyl-α-D-glucopyranoside 
• 1042941-68-3 (4-cyanophenyl)-(4-hydroxyphenyl)methanol 
• 345341-54-0 [4-(4-Cyanobenzoyl)phenyl]2,3,4,6-tetra-O-acetyl-α-D-mannopyranoside 
• 345343-15-9 [4-(4-Cyanobenzoyl)phenyl] 2,3,4,6-tetra-O-acetyl-β-D-mannopyranoside 
• 345343-06-8 [4-(4-Cyanobenzoyl)phenyl] 2,3,4-tri-O-acetyl-β-D-arabinopyranoside 
• 345343-24-0 [4-(4-Cyanobenzoyl)phenyl] 2,3,4-tri-O-acetyl-β-L-xylopyranoside 
• 118909-15-2 1-[2-hydroxy-3-propyl-4-({4-[4-(1H-tetrazol-5-yl)-benzoyl]phenoxy}methyl)phenyl]ethanone 
• 135312-33-3 4-[4-(4-Acetyl-3-hydroxy-2-propyl-benzyloxy)-benzoyl]-benzonitrile 

Relevant articles and documents

COMPOUNS, COMPOSITIONS AND METHODS OF USE

Herein, compounds, compositions and methods for modulating inclusion formation and stress granules in cells related to the onset of neurodegenerative diseases, musculoskeletal diseases, cancer, ophthalmological diseases, and viral infections are described.

Synthesis and structure-activity relationship for new series of 4-phenoxyquinoline derivatives as specific inhibitors of platelet-derived growth factor receptor tyrosine kinase

We discovered a new series of 4-phenoxyquinoline derivatives as potent and selective inhibitors of the platelet-derived growth factor receptor (PDGFr) tyrosine kinase. We researched the highly potent and selective inhibitors on the basis of both PDGFr and epidermal growth factor receptor (EGFr) inhibitory activity. First, we found a compound, Ki6783 (1), which inhibited PDGFr autophosphorylation at 0.13 μM, but it did not inhibit EGFr autophosphorylation at 100 μM. After extensive explorations, we found the two desired compounds, Ki6896 (2) and Ki6945 (3), which are substituted by benzoyl and benzamide at the 4-position of the phenoxy group on 4-phenoxyquinoline, respectively. These inhibitory activities were 0.31 and 0.050 μM, respectively, but neither of them inhibited EGFr autophosphorylation at 100 μM. We further investigated the profile of both compounds toward various tyrosine and serine/threonine kinases. The three compounds specifically inhibited PDGFr rather than the other kinases.

(Phenylmethoxy)phenyl Derivatives of Ω-Oxo- and Ω-Tetrazolylalkanoic Acids and Related Tetrazoles. Synthesis and Evaluation as Leukotriene D4 Receptor Antagonists

Two series of (phenylmethoxy)phenyl compounds derived from the structure of LY163443 were synthesized and evaluated as leukotriene D4 receptor antagonists.In the Ω--Ω-oxoalkanoic acid series, 5-phenyl>-3,3-dimethyl-5-oxopentanoic acid (8) was the most potent antagonist of LTD4-induced contractions of guinea pig ileum (pKB of 7.60) and LTD4 pressor response in pithed rats (ED50 of 1.4 mg/kg iv).Replacing the carboxylic acid function with 5-tetrazole gave slightly more potent compounds.Inthe Ω-alkyl>tetrazolyl>alkanoic acid series, replacing the carboxylic acid with 5-tetrazole gave compounds that were equally effective in the guinea pig ileum but more potent in vivo against the LTD4 pressor response in rat.The pKB value in the guinea pig ileum for 1--2H-tetrazol-5-yl>methyl>phenoxy>methyl>phenyl>ethanone (25) was 7.87 and the ED50 for antagonism of the LTD4 pressor response was 4.0 mg/kg iv.The sodium salts of 8 (9) and 25(26) given by the iv route of administration antagonized LTD4-induced cardiovascular alterations in anesthetized rat and LTD4-induced bronchoconstriction in guinea pig in a dose-dependent manner.Oral activity was also demonstrated against the LTD4-induced bronchoconstriction in guinea pig.